Medivation and Astellas Pharma have launched Xtandi (enzalutamide) capsules for patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.
Xtandi, an oral, once-daily androgen receptor inhibitor approved by the FDA, is being distributed through a network of specialty pharmacies and specialty distributors.
Medivation co-founder, president and chief executive officer David Hung said, "XTANDI was approved by the FDA nearly three months ahead of the action date and we are proud of our accelerated efforts to get this new treatment option to patients with metastatic castration-resistant prostate cancer who have previously received docetaxel."
Astellas and Medivation are also ensuring that patients who are prescribed Xtandi can access the drug in a timely manner through a comprehensive patient access support program.
The FDA has recommended 160 mg dose of Xtandi (four 40 mg capsules) administered orally once daily.
